An amended merger agreement between Abbott Laboratories and Alere, valued at approximately $5.3 billion, has been approved by Alere's shareholders, receiving about 63 million votes of approval, representing over 72.5% of outstanding Alere shares. The deal will make Alere a subsidiary of Abbott and will give Alere shareholders $51 per share.
$5.3B Abbott merger deal secures Alere shareholder approval
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.